Physician profile
Thomas Michael Susko
NPI 1245384106
$7,020.32
in general payments reported to CMS, 2019-2025
18 companies · $406 in 2025
The $406 reported for 2025 was less than what a typical Rheumatology provider received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,988 · 2020: $627 · 2021: $1,198 · 2022: $862 · 2023: $1,173 · 2024: $766 · 2025: $406.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,345.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,345.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $1,245.44 | 2019-2025 | Otezla, Tezspire, Amjevita |
| Janssen Scientific Affairs, LLC | $969.06 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $871.54 | 2019-2024 | |
| Abbvie INC. | $650.06 | 2019-2024 | Rinvoq |
| Ucb, INC. | $620.64 | 2022-2025 | Bimzelx, Cimzia |
| Janssen Biotech, INC. | $571.37 | 2019-2022 | |
| Lilly USA, LLC | $420.28 | 2021-2025 | Taltz |
| Boehringer Ingelheim Pharmaceuticals, INC. | $378.02 | 2021-2025 | Ofev |
| Genzyme Corporation | $232.62 | 2019-2023 | |
| Gilead Sciences, INC. | $211.86 | 2019-2020 | |
| Radius Health, INC. | $132.98 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $124.02 | 2021-2022 | |
| Alexion Pharmaceuticals, INC. | $121.90 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $116.18 | 2021 | |
| Genentech, INC. | $115.54 | 2019 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $109.85 | 2023 | Benlysta |
| Depuy Synthes Sales INC. | $91.34 | 2019-2021 | |
| Horizon Therapeutics Plc | $37.62 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Susko listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.